1. Home
  2. AXSM

as of 12-08-2025 1:57pm EST

$148.24
$0.82
-0.55%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.

Chart Type:
Time Range:
Founded: 2012 Country:
United States
United States
Employees: N/A City: NEW YORK
Market Cap: 5.9B IPO Year: 2015
Target Price: $176.00 AVG Volume (30 days): 551.7K
Analyst Decision: Strong Buy Number of Analysts: 20
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -4.66 EPS Growth: N/A
52 Week Low/High: $75.56 - $152.94 Next Earning Date: 11-03-2025
Revenue: $561,263,000 Revenue Growth: 65.83%
Revenue Growth (this year): 66.2% Revenue Growth (next year): 57.56%

AI-Powered AXSM Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 19 hours ago

AI Recommendation

hold
Model Accuracy: 69.74%
69.74%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Dec 4, 2025

Avg Cost/Share

$148.18

Shares

10,558

Total Value

$1,564,484.44

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Dec 3, 2025

Avg Cost/Share

$146.94

Shares

20,163

Total Value

$2,962,751.22

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Dec 2, 2025

Avg Cost/Share

$144.59

Shares

49,252

Total Value

$7,121,346.68

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Nov 5, 2025

Avg Cost/Share

$134.49

Shares

21,775

Total Value

$2,928,519.75

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Nov 4, 2025

Avg Cost/Share

$133.79

Shares

50,459

Total Value

$6,750,909.61

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Nov 3, 2025

Avg Cost/Share

$132.34

Shares

91,705

Total Value

$12,136,239.70

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Oct 8, 2025

Avg Cost/Share

$118.84

Shares

12,774

Total Value

$1,518,062.16

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Oct 7, 2025

Avg Cost/Share

$118.77

Shares

13,390

Total Value

$1,590,330.30

Owned After

7,229

SEC Form 4

TABUTEAU HERRIOT

Chief Executive Officer

Sell
AXSM Oct 6, 2025

Avg Cost/Share

$120.17

Shares

19,220

Total Value

$2,309,667.40

Owned After

7,229

SEC Form 4

Jacobson Mark L.

Chief Operating Officer

Sell
AXSM Sep 22, 2025

Avg Cost/Share

$115.96

Shares

10,000

Total Value

$1,159,600.00

Owned After

0

SEC Form 4

Share on Social Networks: